Publication
MASLD treatment : a shift in the paradigm is imminent
| Summary: | MASLD prevalence is growing towards the leading cause of end-stage liver disease. Up to today, the most effective treatment is weight loss. Weight loss interventions are moving from lifestyle changes to bariatric surgery or endoscopy, and, more recently, to a new wave of anti-obesity drugs that can compete with bariatric surgery. Liver-targeted therapy is a necessity for those patients who already present liver fibrosis. The field is moving fast, and in the near future, we will testify to a disruptive change in MASLD treatment, similar to the paradigm-shift that occurred for hepatitis C almost one decade ago with direct antiviral agents. |
|---|---|
| Main Authors: | Machado, Mariana |
| Subject: | MASLD Liver disease-targeted drugs Obesity Treatment Weight loss |
| Year: | 2023 |
| Country: | Portugal |
| Document type: | article |
| Access type: | open access |
| Associated institution: | Universidade de Lisboa |
| Language: | English |
| Origin: | Repositório da Universidade de Lisboa |
| _version_ | 1868468377619529728 |
|---|---|
| author | Machado, Mariana |
| author_facet | Machado, Mariana |
| author_role | author |
| contributor_name_str_mv | Repositório Científico de Acesso Aberto da ULisboa |
| country_str | PT |
| creators_json_txt | [{\"Person.name\":\"Machado, Mariana\",\"Person.identifier.orcid\":\"0000-0001-7769-7860\"}] |
| datacite.contributors.contributor.contributorName.fl_str_mv | Repositório Científico de Acesso Aberto da ULisboa |
| datacite.creators.creator.creatorName.fl_str_mv | Machado, Mariana |
| datacite.date.Accepted.fl_str_mv | 2023-01-01T00:00:00Z |
| datacite.date.available.fl_str_mv | 2024-02-29T12:30:59Z |
| datacite.date.embargoed.fl_str_mv | 2024-02-29T12:30:59Z |
| datacite.rights.fl_str_mv | http://purl.org/coar/access_right/c_abf2 |
| datacite.subjects.subject.fl_str_mv | MASLD Liver disease-targeted drugs Obesity Treatment Weight loss |
| datacite.titles.title.fl_str_mv | MASLD treatment : a shift in the paradigm is imminent |
| dc.contributor.none.fl_str_mv | Repositório Científico de Acesso Aberto da ULisboa |
| dc.creator.none.fl_str_mv | Machado, Mariana |
| dc.date.Accepted.fl_str_mv | 2023-01-01T00:00:00Z |
| dc.date.available.fl_str_mv | 2024-02-29T12:30:59Z |
| dc.date.embargoed.fl_str_mv | 2024-02-29T12:30:59Z |
| dc.format.none.fl_str_mv | application/pdf |
| dc.identifier.none.fl_str_mv | http://hdl.handle.net/10451/63037 |
| dc.language.none.fl_str_mv | eng |
| dc.publisher.none.fl_str_mv | Frontiers |
| dc.rights.cclincense.fl_str_mv | http://creativecommons.org/licenses/by/4.0/ |
| dc.rights.none.fl_str_mv | http://purl.org/coar/access_right/c_abf2 |
| dc.subject.none.fl_str_mv | MASLD Liver disease-targeted drugs Obesity Treatment Weight loss |
| dc.title.fl_str_mv | MASLD treatment : a shift in the paradigm is imminent |
| dc.type.none.fl_str_mv | http://purl.org/coar/resource_type/c_6501 |
| description | MASLD prevalence is growing towards the leading cause of end-stage liver disease. Up to today, the most effective treatment is weight loss. Weight loss interventions are moving from lifestyle changes to bariatric surgery or endoscopy, and, more recently, to a new wave of anti-obesity drugs that can compete with bariatric surgery. Liver-targeted therapy is a necessity for those patients who already present liver fibrosis. The field is moving fast, and in the near future, we will testify to a disruptive change in MASLD treatment, similar to the paradigm-shift that occurred for hepatitis C almost one decade ago with direct antiviral agents. |
| dirty | 0 |
| eu_rights_str_mv | openAccess |
| format | article |
| fulltext.url.fl_str_mv | https://repositorio.ulisboa.pt/bitstreams/0f6c3e8b-2d9b-43ec-ab9a-508612c4892f/download |
| id | ul_4e6baebfc64aa8d7e9a53fa00009b6c2 |
| identifier.url.fl_str_mv | http://hdl.handle.net/10451/63037 |
| instacron_str | ul |
| institution | Universidade de Lisboa |
| instname_str | Universidade de Lisboa |
| language | eng |
| network_acronym_str | ul |
| network_name_str | Repositório da Universidade de Lisboa |
| oai_identifier_str | oai:repositorio.ulisboa.pt:10451/63037 |
| organization_str_mv | urn:organizationAcronym:ul |
| person_str_mv | Machado, Mariana Machado, Mariana http://orcid.org/0000-0001-7769-7860 0000-0001-7769-7860 |
| publishDate | 2023 |
| publisher.none.fl_str_mv | Frontiers |
| reponame_str | Repositório da Universidade de Lisboa |
| repository_id_str | urn:repositoryAcronym:ul |
| service_str_mv | urn:repositoryAcronym:ul |
| spelling | engFrontierspt_PTMASLD prevalence is growing towards the leading cause of end-stage liver disease. Up to today, the most effective treatment is weight loss. Weight loss interventions are moving from lifestyle changes to bariatric surgery or endoscopy, and, more recently, to a new wave of anti-obesity drugs that can compete with bariatric surgery. Liver-targeted therapy is a necessity for those patients who already present liver fibrosis. The field is moving fast, and in the near future, we will testify to a disruptive change in MASLD treatment, similar to the paradigm-shift that occurred for hepatitis C almost one decade ago with direct antiviral agents.application/pdfpt_PTMASLD treatment : a shift in the paradigm is imminentPersonalMachado, MarianaDSpacehttp://dspace.org/items/cfad9e93-f680-4e18-864f-b3954ee025edDSpacehttp://dspace.org/items/cfad9e93-f680-4e18-864f-b3954ee025edMachadoMarianaORCIDhttp://orcid.org0000-0001-7769-7860HostingInstitutionOrganizationalRepositório Científico de Acesso Aberto da ULisboae-mailmailto:repositorio@reitoria.ulisboa.ptrepositorio@reitoria.ulisboa.ptDOIIsPartOf10.3389/fmed.2023.13162842024-02-29T12:30:59Z20232023-01-01T00:00:00ZHandlehttp://hdl.handle.net/10451/63037http://purl.org/coar/access_right/c_abf2open accessMASLDLiver disease-targeted drugsObesityTreatmentWeight loss875845 bytesliteraturehttp://purl.org/coar/resource_type/c_6501journal article2023http://creativecommons.org/licenses/by/4.0/http://purl.org/coar/access_right/c_abf2application/pdffulltexthttps://repositorio.ulisboa.pt/bitstreams/0f6c3e8b-2d9b-43ec-ab9a-508612c4892f/downloadFrontiers in Medicine10 |
| spellingShingle | MASLD treatment : a shift in the paradigm is imminent Machado, Mariana MASLD Liver disease-targeted drugs Obesity Treatment Weight loss |
| status | SINGLETON |
| subject.fl_str_mv | MASLD Liver disease-targeted drugs Obesity Treatment Weight loss |
| title | MASLD treatment : a shift in the paradigm is imminent |
| title_full | MASLD treatment : a shift in the paradigm is imminent |
| title_fullStr | MASLD treatment : a shift in the paradigm is imminent |
| title_full_unstemmed | MASLD treatment : a shift in the paradigm is imminent |
| title_short | MASLD treatment : a shift in the paradigm is imminent |
| title_sort | MASLD treatment : a shift in the paradigm is imminent |
| topic | MASLD Liver disease-targeted drugs Obesity Treatment Weight loss |
| topic_facet | MASLD Liver disease-targeted drugs Obesity Treatment Weight loss |
| url | http://hdl.handle.net/10451/63037 |
| visible | 1 |